MRD Clinical Portfolio

Pipeline

Measure MRD

clonoSEQ by Adaptive Logo

EARLY
DEVELOPMENT

AV/CV

CLIA/FDA

COMMERCIALIZED

ALL

EARLY
DEVELOPMENT

AV/CV

CLIA/FDA

COMMERCIALIZED

FDA cleared

Bone Marrow

CLIA Validated

Blood

CLL

EARLY
DEVELOPMENT

AV/CV

CLIA/FDA

COMMERCIALIZED

FDA cleared

Bone Marrow

FDA cleared

Blood

MM

EARLY
DEVELOPMENT

AV/CV

CLIA/FDA

COMMERCIALIZED

FDA cleared

Bone Marrow

CLIA Validated

Blood

NHL1

EARLY
DEVELOPMENT

AV/CV

CLIA/FDA

COMMERCIALIZED

CLIA Validated

cfDNA (DLBCL)

CLIA Validated

Blood

1 Available to order as a CLIA-validated laboratory developed test (LDT) service. This use has not been cleared or approved by the FDA.

clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary